Two Sumitovant Biopharma entities are merging under one name, effective immediately.
CARY, N.C. and BASEL, Switzerland, May 6, 2022 /PRNewswire/ -- Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, announced today that the company is presenting results from a preclinical study comparing rodatristat ethyl as a monotherapy and in combination with the type A endothelin receptor antagonist, ambrisentan, in an animal model of pulmonary arterial hypertension (PAH). Results describing changes in post-hypoxia occlusions as well as mean pulmonary arterial pressure (mPAP) with each treatment regimen will be presented in a poster at ATS 2022 being held in San Francisco, CA, May 13-18, 2022.
Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, announced...
CARY, N.C. and BASEL, Switzerland, April 25, 2022 /PRNewswire/ -- Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, announced today that the company will make an oral presentation on preclinical results supporting the development of ALTA-2530 for the treatment of bronchiolitis obliterans syndrome (BOS). Altavant will also share a poster presentation summarizing the research to understand patient insights in BOS/chronic lung allograft dysfunction (CLAD) at the International Society for Heart & Lung Transplantation (ISHLT) annual meeting, April 27-30, 2022, in Boston, MA.
CARY, N.C. and BASEL, Switzerland, Sept. 13, 2021 /PRNewswire/ -- Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, presented an e-poster at the European Respiratory Society annual congress highlighting the protocol and design of the ongoing double-blind, placebo-controlled ELEVATE 2 (NCI NCT04712669) Phase 2b study of rodatristat ethyl (rodatristat) in patients with pulmonary arterial hypertension (PAH).
CARY, N.C. and BASEL, Switzerland, May 20, 2021 /PRNewswire/ -- Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, presented an update on the clinical development of rodatristat ethyl, the company's lead candidate for the treatment of pulmonary arterial hypertension (PAH), at the recent meeting of the American Thoracic Society (ATS). This update included findings from a dose-response model, which simulated daily administration of rodatristat ethyl to identify optimal doses for the Phase 2b clinical trial.
CARY, N.C. and BASEL, Switzerland, May 10, 2021 /PRNewswire/ -- Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, will be providing an update on the clinical development of rodatristat ethyl, the company's lead candidate for the treatment of pulmonary arterial hypertension (PAH), at the annual meeting of the American Thoracic Society (ATS), being held virtually on May 14-19, 2021.
CARY, N.C. and BASEL, Switzerland, May 10, 2021 /PRNewswire/ -- Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, will be providing an update on the clinical development of rodatristat ethyl, the company's lead candidate for the treatment of pulmonary arterial hypertension (PAH), at the annual meeting of the American Thoracic Society (ATS), being held virtually on May 14-19, 2021.
Cary, N.C. and Basel, Switzerland, April 26, 2021 (GLOBE NEWSWIRE) -- – Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, presented results of in vitro and in vivo studies for nebulized ALTA-2530, a novel inhaled formulation of recombinant human IL-1 receptor antagonist (rhIL-1Ra) currently in nonclinical development for the treatment of bronchiolitis obliterans syndrome (BOS). These studies demonstrated that ALTA-2530 achieved and maintained pharmacologically relevant exposure levels in lung epithelial lining fluid and distributed to epithelial cells of the lung’s distal airways. Additional studies demonstrated the rhIL-1Ra protein was stable and retained full potency during nebulization. Together, these findings support the further investigation of ALTA-2530 for the treatment of BOS, a life-threatening form of chronic lung allograft dysfunction (CLAD) that leads to fibrosis of the small airways (bronchioles) and eventual partial or total obstruction of the distal airways.
Cary, N.C. and Basel, Switzerland, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, today presented results from in vivo nonclinical studies of rodatristat ethyl, a TPH inhibitor in clinical development for PAH. The studies demonstrated enhanced distribution of rodatristat ethyl in lung tissue consistent with levels associated with disease modification in preclinical models and also demonstrated minimal brain exposure supporting a lack of impact on brain serotonin levels. These findings were presented in a thematic poster session at the annual meeting of the American Thoracic Society on August 5, 2020.